Eliminate Viral Hepatitis

Each year, around 630 Australians and 500,000 people globally die from hepatitis C-related causes.

Eliminating hepatitis C virus (HCV) in Australia is now a possibility, with the listing of direct-acting antiviral (DAA) drugs on the PBS. But this is one step in the path towards elimination.

Burnet will also make a major contribution in global efforts to eliminate hepatitis B & C as major health threats. This includes supporting vital research underway by our researchers to create a novel, effective, low-cost HCV vaccine suitable for resource-constrained countries.

Burnet Institute’s Eliminate Viral Hepatitis strategy is focussed on:

  • Achieving a 50 percent reduction in hepatitis C prevalence in Australia by 2020.
  • Supporting the achievement of the WHO’s hepatitis C elimination targets in Australia before 2030 with key partners.
  • Working towards Global WHO viral hepatitis elimination strategy by addressing diagnosis, delivery of direct-acting antivirals, prevention and vaccine development.

Working together, with research organisations, governments, the community and affected populations, Burnet will help change the course of hepatitis C infection and its impact as a public health threat.

Hepatitis C virus (HCV) affects more than 250,000 Australians resulting in up to 630 deaths from liver cancer and liver failure each year. Globally, more than 500,000 people die from HCV-related causes.

The ambitious journey to eliminate viral hepatitis has begun.

Download

Contact Details

Professor Margaret Hellard AM

Deputy Director (Programs); Adjunct Professor, Monash University, DEPM.

Telephone

+61385062304

Email

[email protected]


Projects

  • ACCESS: The Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmitted Infections

  • Cancer information compared to Hepatitis B information to INcreAse hepatitis B testing in Melbourne’s Chinese community (CHINA-B study)

  • co-EC Study: Eliminating hepatitis C/HIV coinfection

  • DARE C: ATAHC II Substudy

  • Decision science using Optima

  • Development of a universal prophylactic vaccine for Hepatitis C

  • EC Australia: Eliminate Hepatitis C Australia Partnership

  • EC Partnership: Eliminate Hepatitis C Partnership

  • Feasibility and Outcomes of the Public Sector Hepatitis C Treatment Program in Myanmar

  • HCV Elimination Modelling

  • Hepatitis B discrimination and health service access.

  • Hepatitis B Modelling

  • Hepatitis C brief reports

  • Hepatitis C: Community Testing and Treatment (CT2)

  • Identifying the barriers to hepatitis B clinical management: the perspectives of people with hepatitis B.

  • Identifying the structural enablers to the clinical management of people with hepatitis B in general practice: a qualitative investigation

  • Improving Hepatitis B Virus screening in general practice in Victoria

  • Methods for improved sensitivity of lateral flow tests

  • Modelling for evidence-based national hepatitis B testing plans

  • Modelling hepatitis C virus elimination and control policies in Myanmar

  • Natural history and response to treatment recent hepatitis C virus infection among a cluster of HCV genotype-1b infected individuals

  • SHARP: Screening for Hepatitis in At-Risk Populations

  • Social Networks and the Hepatitis C Virus

  • The Australian Trial in Acute Hepatitis C (ATAHC)

  • The elimination of hepatitis C as a global public health threat

  • The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)

  • The PharmEC REACH study

  • The QuickStart Study

  • Understanding how HCV evades the immune system

  • Understanding the correlates of protection for hepaciviruses

  • What drives hepatitis C reinfection?

Latest News